目的探讨Noxa表达水平与胃癌患者临床特征及预后的关系。方法研究纳入2013年1月至2015年5月确诊并接受治疗的胃癌患者60例,其中男32例,女28例;中位年龄65岁(38~76岁)。收集术中胃癌组织标本和对应的癌周正常组织标本。实时荧光定量PCR检测胃癌组织和癌周组织中Noxa mRNA的水平,免疫组织化学检测胃癌组织和癌周组织中Noxa的蛋白表达水平。分析胃癌组织中Noxa表达与患者性别、年龄、肿瘤部位、肿瘤大小、浸润深度、转移情况等临床病理特征的关系。同时探讨Noxa表达与患者预后的关系。结果实时荧光定量PCR结果显示胃癌组织中的Noxa mRNA低于癌周正常组织,差异具有统计学意义(P<0.05)。免疫组化结果显示胃癌组织Noxa阳性表达率为43.3%,癌周正常组织的Noxa阳性表达率88.3%,差异具有统计学意义(P<0.05)。肿瘤直径不同、浸润深度不同、淋巴结和远隔器官转移情况不同的患者,其Noxa表达水平具有统计学差异(P<0.01,P<0.05)。Noxa表达阳性患者2年生存率为60.1%,Noxa表达阴性患者的2年生存率为42.9%,差异具有统计学意义(P<0.05)。结论 Noxa具有成为胃癌临床诊断或评估分子标志物的潜能,Noxa的低表达预示着胃癌患者的不良预后。 Objective To investigate the relationship between the expression level of Noxa and clinical characteristics and prognosis of gastric cancer patients. METHODS: Sixty patients diagnosed and treated with gastric cancer from January 2013 to May 2015 were included in the study, including 32 males and 28 females; the median age was 65 years (38-76 years). The intraoperative gastric cancer tissue samples and the corresponding normal tissue samples of the cancerous tissues were collected. Real-time fluorescence quantitative PCR was used to detect the expression of Noxa mRNA in gastric cancer tissues and pericancerous tissues. Immunohistochemistry was used to detect the protein expression level of Noxa in gastric cancer tissues and pericancerous tissues. The relationship between the expression of Noxa in gastric cancer and the clinicopathological features such as sex, age, tumor location, tumor size, invasion depth and metastasis was analyzed. At the same time explore the relationship between the expression of Noxa and the prognosis of patients. Results The results of real-time fluorescence quantitative PCR showed that the expression of Noxa mRNA in gastric cancer tissues was lower than that in normal tissues around the cancer, and the difference was statistically significant (P<0.05). The results of immunohistochemistry showed that the positive rate of Noxa in gastric cancer tissues was 43.3%, and the positive rate of Noxa in cancer tissues was 88.3%. The difference was statistically significant (P<0.05). There were significant differences in the expression of Noxa between patients with different tumor diameters, different infiltration depths, and different metastasis of lymph nodes and distant organs (P<0.01, P<0.05). The 2-year survival rate of patients with positive Noxa expression was 60.1%, and the 2-year survival rate of patients with Noxa negative expression was 42.9%. The difference was statistically significant (P<0.05). Conclusions Noxa has the potential to become a molecular marker for clinical diagnosis or evaluation of gastric cancer. The low expression of Noxa predicts a poor prognosis in patients with gastric cancer.